Gene · 151306
Papers2,833
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,833
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Loss of TGR5-activating bile acids is associated with disease activity in inflammatory bowel disease. | Sci Rep | 2026 | 42481656 | PubTator, text mining | PubMed |
| Orchestrating the gut microbiota-mitochondrial-immune axis in gynecological diseases: mechanisms and dual-targeting therapeutic strategies. | Front Reprod Health | 2026 | 42460096 | PubTator, text mining | PubMed |
| Multidimensional regulatory mechanisms and targeted intervention strategies of the gut-joint axis in metabolic osteoarthritis. | Transl Res | 2026 | 42448219 | PubTator, text mining | PubMed |
| Microbiome-metabolite signaling networks in gastrointestinal disease: systems biology, network rewiring, and precision therapeutics. | Arch Microbiol | 2026 | 42440156 | PubTator, text mining | PubMed |
| Taurochenodeoxycholic acid alleviates MPP+/MPTP-induced neurotoxicity in vitro and in vivo by suppressing ferroptosis via TGR5/cGAS/STING signaling pathway. | IBRO Neurosci Rep | 2026 | 42437012 | PubTator, text mining | PubMed |
| Network pharmacology combined with molecular docking to investigate the potential role of curcumin targeting TGR5 to modulate the GLP-1 pathway in T2DM with obesity. | Pak J Pharm Sci | 2026 | 42433074 | PubTator, text mining | PubMed |
| Gut Microbiota, Immunity, and Metabolism in the Progression From Chronic Liver Disease to Hepatocellular Carcinoma. | Adv Sci (Weinh) | 2026 | 42429613 | PubTator, text mining | PubMed |
| Phytochemicals remodel antitumor immunity via the "microbiota-metabolite-receptor" axis: focus on colorectal cancer and immunotherapy. | Med Oncol | 2026 | 42418125 | PubTator, text mining | PubMed |
| Dysregulation of the bile acid signaling network in non-alcoholic fatty liver disease: Mechanisms and a new paradigm of precision network pharmacology. | Biochem Pharmacol | 2026 | 42409325 | PubTator, text mining | PubMed |
| Beyond dysbiosis: microbial metabolites as key remodelers of nasal mucosal immune tolerance in chronic rhinosinusitis. | Front Immunol | 2026 | 42382746 | PubTator, text mining | PubMed |
| Discovery of sulfonyl benzoic acid derivatives with joint TGR5-agonist and FXR-antagonist activity for myocardial ischemia/reperfusion injury protection. | Acta Pharm Sin B | 2026 | 42368574 | PubTator, text mining | PubMed |
| Gut microbiota metabolites in inflammatory bowel disease: advances in mechanistic insights. | Front Immunol | 2026 | 42358979 | PubTator, text mining | PubMed |
| GDF15 (Growth/Differentiation Factor-15) Expression in Human Adipose Tissue and in Adipocyte Cell Lines. | Biomedicines | 2026 | 42351757 | PubTator, text mining | PubMed |
| Bile Acids and the Gut-X Axis: TCM-Mediated Systemic Protection and Therapeutic Opportunities for Multi-Organ Diseases. | Metabolites | 2026 | 42346347 | PubTator, text mining | PubMed |
| Takeda G-protein-coupled receptor 5 and farnesoid X receptor agonists for diabetes treatment: a patent review and clinical advancements (2015-present). | Expert Opin Ther Pat | 2026 | 42331759 | PubTator, text mining | PubMed |
| Bile acids and bile acid modification in health and disease: from novel modifications to therapeutic interventions. | Front Endocrinol (Lausanne) | 2026 | 42325611 | PubTator, text mining | PubMed |
| Emerging Trends and Research Hotspots in Gut Microbiota-Liver Fibrosis Research (2008-2025): A Bibliometric Analysis. | J Nutr | 2026 | 42323132 | PubTator, text mining | PubMed |
| Gut microbiota, brown adipose tissue whitening, and obesity: nutritional modulators and metabolic crosstalk. | Nutr Metab (Lond) | 2026 | 42304377 | PubTator, text mining | PubMed |
| The interplay between bile acid metabolism and gut microbiome in biliary tract cancers. | Front Microbiomes | 2026 | 42293159 | PubTator, text mining | PubMed |
| Author Correction: Inhibition of fatty acid uptake by TGR5 prevents diabetic cardiomyopathy. | Nat Metab | 2026 | 42265389 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/151306/papers?page=3